Incyte Corporation (INCY) vs West Pharmaceutical Services, Inc. (WST)
A side-by-side comparison of Incyte Corporation and West Pharmaceutical Services, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of September 13, 2026. Differences are shown without an overall score or investment verdict.
INCY
Incyte Corporation
$123.89HealthcareDelayed quote: Sep 25, 2026, 4:00 PM EDT
WST
West Pharmaceutical Services, Inc.
$370.29HealthcareDelayed quote: Sep 25, 2026, 4:00 PM EDT
Total return — INCY vs WST
growth of $100 · dividends reinvested · last 10yINCY +55.8% (+4.5%/yr)WST +329.4% (+15.7%/yr)WST compounded faster over this window
INCY WST
INCY vs WST: by the numbers
- •WST is the larger company ($26.06B vs $25.11B market cap).
- •INCY trades at the lower trailing earnings multiple (15.78 vs 47.35 P/E), one valuation lens rather than an overall verdict.
- •INCY converts more revenue to profit (27.71% vs 16.98% net margin).
- •INCY grew revenue faster over the past five years (16.43% vs 5.68% CAGR).
- •WST pays a dividend (0.26% yield), while INCY has no payments in the available dividend history.
Metrics side by side
Valuation
| Metric | INCY | WST |
|---|---|---|
| P/E ratio | 15.78 | 47.35 |
| Forward P/E | 32.93 | 41.30 |
| P/S ratio | 4.32 | 7.83 |
| P/B ratio | 3.96 | 8.71 |
| EV / EBITDA | 10.94 | 29.92 |
| FCF yield | 7.65% | 1.68% |
Profitability
| Metric | INCY | WST |
|---|---|---|
| Gross margin | 92.62% | 36.77% |
| Operating margin | 31.57% | 20.64% |
| Net margin | 27.71% | 16.98% |
| ROE | 25.41% | 18.89% |
| ROIC | 22.95% | 15.77% |
Dividends
| Metric | INCY | WST |
|---|---|---|
| Dividend yield | N/A | 0.26% |
| Payout ratio | N/A | 11.25% |
Growth (annualized)
| Metric | INCY | WST |
|---|---|---|
| Revenue CAGR (5Y) | 16.43% | 5.68% |
| EPS CAGR (5Y) | 21.19% | 7.85% |
| FCF CAGR (5Y) | 33.69% | 8.74% |
| Total return CAGR (5Y) | 11.30% | -5.84% |
Frequently asked
- Which has the lower trailing P/E, INCY or WST?
- INCY has the lower trailing P/E: INCY trades at 15.78 and WST at 47.35. P/E is one valuation measure and does not by itself establish which business is cheaper.
- Which has grown faster, INCY or WST?
- Over the past five years, INCY grew revenue faster — INCY at a 16.43% CAGR versus WST at 5.68%.
- Does INCY or WST pay a bigger dividend?
- WST pays a dividend (0.26% yield), while INCY has no payments in the available dividend history.
- Is INCY or WST more profitable?
- INCY runs the higher net margin — INCY at 27.71% versus WST at 16.98%.
- How have INCY and WST total returns compared?
- Over the past 10 years, INCY delivered 4.38% and WST delivered 15.86% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Incyte P/E ratioWest Pharmaceutical Services P/E ratioWest Pharmaceutical Services dividend yieldIncyte ROEWest Pharmaceutical Services ROEIncyte operating marginWest Pharmaceutical Services operating marginIncyte revenue growthWest Pharmaceutical Services revenue growthIncyte free cash flowWest Pharmaceutical Services free cash flow
Incyte & West Pharmaceutical Services appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified September 13, 2026.